OncoMatch/Clinical Trials/NCT05905887
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Is NCT05905887 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Rivoceranib Mesylate, Paclitaxel for gastrointestinal stromal tumors.
Treatment: Rivoceranib Mesylate, Paclitaxel — The purpose of this study is to evaluate the efficacy and safety of rivoceranib and paclitaxel combination therapy in patients with P-glycoprotein overexpressing GIST who failed standard treatment with imatinib, sunitinib, and regorafenib.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Gastrointestinal Stromal Tumor
Biomarker criteria
Required: KIT mutation
mutation in KIT or PDGFRα gene
Required: PDGFRA mutation
mutation in KIT or PDGFRα gene
Required: KIT overexpression (CD117+) (CD117(+))
CD117(+)
Required: ABCB1 overexpression (P-glycoprotein IHC score > 3) (IHC score > 3)
P-glycoprotin IHC score > 3
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: tyrosine kinase inhibitor (imatinib, sunitinib, regorafenib)
Failed (progressed and/or intolerable) after prior treatments for GIST, including at least imatinib and sunitinib, regorafenib.
Lab requirements
Blood counts
Neutrophil >1,500/mm3; Platelet > 100,000/mm3; Hemoglobin >8.0 g/dL
Kidney function
Creatinine <1.5 x ULN
Liver function
Total bilirubin < 1.5 x ULN; AST/ALT < 2.5 x ULN
Adequate bone marrow, hepatic, renal, and other organ functions Neutrophil >1,500/mm3 Platelet > 100,000/mm3 Hemoglobin >8.0 g/dL Total bilirubin < 1.5 x upper limit of normal (ULN) AST/ALT < 2.5 x ULN Creatinine <1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05905887 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received tyrosine kinase inhibitor.
Does this trial require KIT?
Yes, KIT mutation is a required biomarker for enrollment.
Does this trial require PDGFRA?
Yes, PDGFRA mutation is a required biomarker for enrollment.
Does this trial require KIT?
Yes, KIT overexpression (CD117+) is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify